Neurelis vs Genentech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Neuroscience pharma commercializing VALTOCO (diazepam nasal spray) for seizure clusters. ~$295-300M estimated net sales in 2025; 30%+ EBITDA margin; no bank debt.
About
Neurelis is a private neuroscience-focused pharmaceutical company dedicated to developing and commercializing therapies for epilepsy and neurological disorders. Its lead commercial product, VALTOCO (diazepam nasal spray), is an FDA-approved treatment for acute seizure clusters in patients aged two and older — a label expansion to children ages two to five was approved in April 2025. The company reported estimated net sales of $295–300 million for 2025, more than doubling 2024 revenue, with an EBITDA margin exceeding 30% and a debt-free balance sheet holding $175M+ in cash. VALTOCO''s Orange Book patent portfolio now includes six listed patents, extending exclusivity to October 2032. Neurelis is using this commercial momentum to advance its CNS pipeline and pursue additional products.
Roche subsidiary and founding biotech; invented the biologics industry with recombinant DNA. Blockbuster oncology franchise includes Herceptin, Avastin, Rituxan, and Tecentriq.
About
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching the modern biotechnology industry. Acquired by Roche in 2009 for $46.8 billion, Genentech continues to operate with significant R&D autonomy as the US hub for Roche's pharmaceutical innovation.\n\nThe company is best known for pioneering cancer biologics, developing Herceptin (trastuzumab) for HER2-positive breast cancer, Avastin (bevacizumab) for multiple cancers, Rituxan (rituximab) for lymphoma, and Tecentriq (atezolizumab) for PD-L1 immunotherapy. Its discovery engine spans oncology, neuroscience, ophthalmology, and immunology with a robust early-stage pipeline leveraging AI-assisted target identification.\n\nGenentech generates tens of billions in annual revenue through Roche's Pharmaceuticals Division and remains one of the most productive biotech research sites in the world, consistently ranked among top employers in life sciences. The South San Francisco campus employs over 13,000 scientists, clinicians, and engineers, anchoring the Bay Area as a global biotech hub.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.